Neuvo Supertech Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-05-2024
- Paid Up Capital ₹ 0.90 M
as on 18-05-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
About Neuvo Supertech Pharmaceutical
The Corporate was formerly known as Neuvo Supertech Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Neel Jain and Kanishk Ranka serve as directors at the Company.
- CIN/LLPIN
U24100GJ2009PTC057206
- Company No.
057206
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jun 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Neuvo Supertech Pharmaceutical Private Limited offer?
Neuvo Supertech Pharmaceutical Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine.
Who are the key members and board of directors at Neuvo Supertech Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanishk Ranka  | Director | 25-Jun-2018 | Current |
| Neel Jain | Director | 17-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Neuvo Supertech Pharmaceutical.
Neuvo Supertech Pharmaceutical Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Neuvo Supertech Pharmaceutical?
In 2017, Neuvo Supertech Pharmaceutical had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neuvo Supertech Pharmaceutical?
Unlock and access historical data on people associated with Neuvo Supertech Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuvo Supertech Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuvo Supertech Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
